United States Atherosclerosis Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Atherosclerosis Drugs Market reached US$ 26.4 billion in 2023 and is expected to reach US$ 32.5 billion by 2031 growing with a CAGR of 2.6% during the forecast period 2024-2031.

Key Development:

United States: Recent Industry Developments

✅ In October 2025, Amgen announced a significant move by offering its cholesterol-lowering drug, Repatha, directly to U.S. consumers at a 60% discount, pricing it at $239 per month. This initiative aims to enhance accessibility for uninsured or cash-paying patients and aligns with efforts to reduce prescription drug costs.

✅ In October 2025, AstraZeneca reported a successful late-stage trial for its hypertension drug, baxdrostat, showing substantial reductions in blood pressure among patients with resistant hypertension. The company anticipates regulatory approval and potential annual sales of up to $5 billion.

✅ In October 2025, Amgen's VESALIUS-CV trial met its primary endpoints in a cardiovascular primary prevention study involving over 12,000 patients with atherosclerotic cardiovascular disease or high-risk diabetes. The study's success underscores the potential of PCSK9 inhibitors in reducing cardiovascular events.

Japan: Recent Industry Developments

✅ In September 2025, Otsuka Pharmaceutical Co., Ltd. received approval from the Japanese Ministry of Health, Labour and Welfare for NEXLETOL® (bempedoic acid) as a treatment for hypercholesterolemia and familial hypercholesterolemia. This approval expands treatment options for patients with high cholesterol levels.

✅ In August 2025, Bayer announced the acquisition of rights to an experimental heart drug from Cytokinetics in Japan. The collaboration aims to develop treatments for hypertrophic cardiomyopathy, a condition affecting the heart's pumping function, enhancing Bayer's cardiovascular portfolio.

✅ In February 2025, Bain Capital acquired Tanabe Pharma, a 340-year-old pharmaceutical company, for $3.3 billion. This acquisition is part of Bain's strategy to accelerate drug development in Japan, particularly for rare diseases, and to address regulatory challenges in the Japanese pharmaceutical sector.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/atherosclerosis-drugs-market?sb

Recent Mergers and acquisitions:

United States: Recent M&A Activity

✅ In June 2025, Eli Lilly announced its acquisition of Verve Therapeutics for up to $1.3 billion. This strategic move aims to advance gene-editing therapies targeting PCSK9 to permanently lower LDL-C levels, addressing the root causes of atherosclerotic cardiovascular disease (ASCVD).

✅ In September 2025, Novartis agreed to acquire Tourmaline Bio for $1.4 billion. This acquisition enhances Novartis's cardiovascular pipeline with pacibekitug, an anti-IL-6 monoclonal antibody in Phase 3 development for treating ASCVD.

Key Players:

=> Pfizer Inc, AstraZeneca, Merck & Co., Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, GSK plc, Bayer AG, CSL and New Amsterdam Pharma Company N.V. among others.

Growth Forecast Projected:

The Global Atherosclerosis Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Atherosclerosis Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=atherosclerosis-drugs-market

Key Segments:

➥ By Drug Type: Anti-platelet & Anticoagulants, Cholesterol Lowering Medication, ACE Inhibitors, Fibric Acid and Omega-3 Fatty Acid Derivatives, Beta Blockers, Others

➥ By Route of Administration: Oral, Injectable

➥ By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Atherosclerosis Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Atherosclerosis Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Atherosclerosis Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/atherosclerosis-drugs-market?sb

FAQ

What is the current size of the Atherosclerosis Drugs Market?

A: In 2023, the Atherosclerosis Drugs Market was valued at US$ 26.4 billion, reflecting its strong industry presence.

Q2: How large is the Atherosclerosis Drugs Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Atherosclerosis Drugs Market will grow to around US$ 32.5 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Atherosclerosis Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 2.6% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.